Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
0.5979
+0.0369 (6.58%)
At close: Oct 15, 2026, 4:00 PM EDT
0.5680
-0.0299 (-5.00%)
After-hours: Oct 15, 2026, 7:58 PM EDT
Ensysce Biosciences Revenue
Ensysce Biosciences had revenue of $1.16M in the quarter ending June 30, 2026, a decrease of -15.10%. This brings the company's revenue in the last twelve months to $4.50M, down -39.29% year-over-year. In the year 2025, Ensysce Biosciences had annual revenue of $5.07M, down -2.75%. That makes Ensysce Biosciences the 40,260th largest company in the world by revenue and 5,368th in the United States.
Revenue (ttm)
$4.50M
Revenue Growth
-39.29%
P/S Ratio
2.51
Revenue / Employee
$450,075
Employees
10
Market Cap
11.63M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.07M | -143.38K | -2.75% |
| Dec 31, 2024 | 5.21M | 2.98M | 133.58% |
| Dec 31, 2023 | 2.23M | -292.86K | -11.61% |
| Dec 31, 2022 | 2.52M | -1.01M | -28.54% |
| Dec 31, 2021 | 3.53M | -400.01K | -10.18% |
| Dec 31, 2020 | 3.93M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
ENSC News
- 21 days ago - Ensysce Biosciences submits Phase 2 protocol for CY200 to UK MHRA - TheFly
- 21 days ago - Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA - Accesswire
- 4 weeks ago - Ensysce Biosciences advances CRPS program at Painweek 2026 - TheFly
- 4 weeks ago - Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation - Accesswire
- 4 weeks ago - Ensysce professor to speak at FDA public hearing on psychedelic drugs - TheFly
- 4 weeks ago - Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs - Accesswire
- 6 weeks ago - Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation - Accesswire
- 6 weeks ago - Ensysce completes enrollment for final phase of PF614-MPAR-102 study - TheFly